Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06408259 · ClinicalTrials.gov registry record · Phase 3

Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis

A Phase 3 study of Multiple Sclerosis (Relapsing Remitting), sponsored by Celgene.

Recruiting
Registry status
Phase 3
Development phase
194
Enrollment target
20
Study locations

NCT06408259 is a Phase 3 study of Multiple Sclerosis (Relapsing Remitting) that is actively recruiting participants, run by Celgene. The registered enrollment target is 194 participants, below the 556-participant average among 29 other Multiple Sclerosis (Relapsing Remitting) trials with a reported enrollment target (65% lower). The trial reports 20 study locations across 16 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06408259, a Phase 3 study of Multiple Sclerosis (Relapsing Remitting), is actively recruiting participants, sponsored by Celgene.

RECRUITING
Registry status
Phase 3
Development phase
194 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the effectiveness, safety, tolerability, drug levels and drug effects of ozanimod compared to fingolimod in children and adolescents with relapsing remitting multiple sclerosis (RRMS).

Conditions Studied

Multiple Sclerosis (Relapsing Remitting)

Interventions

  • OTHER Placebo
  • DRUG Ozanimod
  • DRUG Fingolimod

Study Locations (20)

California

  • Local Institution - 0114 - Loma Linda
  • University of California Davis Health - Sacramento

Illinois

  • Local Institution - 0093 - Chicago
  • University of Chicago Medical Center - Chicago

New Jersey

  • Local Institution - 0131 - New Brunswick
  • Local Institution - 0132 - Teaneck

Lombardy

  • Ospedale San Raffaele - Milan
  • Local Institution - 0081 - Milan

Florida

  • University of South Florida - Tampa

Kentucky

  • Local Institution - 0047 - Louisville

Ohio

  • Local Institution - 0091 - Cincinnati

Oregon

  • Local Institution - 0092 - Portland

Trial Details

FieldValue
Enrollment Target 194 participants
Start Date 2025-04-08
Est. Completion 2036-07-13
Phase Phase 3

Sponsor

Celgene

308 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06408259

The ClinicalTrials.gov registry entry for NCT06408259 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 194 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 556-participant average among 29 other Multiple Sclerosis (Relapsing Remitting) trials with a reported enrollment target (65% lower). The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Sclerosis (Relapsing Remitting) appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT06408259 reports 20 study locations spanning 16 distinct geographic areas - top geographies include California, Illinois, New Jersey.

Frequently Asked Questions

What is clinical trial NCT06408259 about?

NCT06408259 is a clinical study titled "Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis". The purpose of this study is to evaluate the effectiveness, safety, tolerability, drug levels and drug effects of ozanimod compared to fingolimod in children and adolescents with relapsing remitting multiple sclerosis (RRMS).

What is the current status of trial NCT06408259?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 194 participants. The study started on 2025-04-08. Estimated completion is 2036-07-13.

What conditions does trial NCT06408259 study?

This clinical trial studies the following conditions: Multiple Sclerosis (Relapsing Remitting).

What interventions are being tested in trial NCT06408259?

The interventions under investigation include: Placebo (OTHER), Ozanimod (DRUG), Fingolimod (DRUG).

Who is sponsoring clinical trial NCT06408259?

This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06408259 being conducted?

This trial has 20 study locations across California, Florida, Illinois, Kentucky, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Sclerosis (Relapsing Remitting)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Sclerosis (Relapsing Remitting)

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.